Corporate Responsibility

October 13, 2021 Alnylam Challengers - a Health Equity Community Impact Program Alnylam Challengers is Alnylam's signature CSR Community Impact Program. It aims to improve health access to underserved communities. Read More ›
March 11, 2021 Alnylam Publishes First Corporate Responsibility Summary Today, we've published Alnylam's first Corporate Responsibility Summary detailing our approach to corporate responsibility and the actions we are and intend to Read More ›
February 6, 2021 Alnylam Named to Bloomberg's 2021 Gender-Equality Index Alnylam has been selected to Bloomberg's Gender-Equality Index for 2021 Read More ›
December 7, 2020 Alnylam Releases 2nd Annual Patient Access Philosophy Report The 2020 Alnylam Patient Access Philosophy Report details Alnylam's progress against key metrics related to patient access to its innovative RNAi therapeutics. Read More ›
October 1, 2020 A New European Biotech Social Pact The European Pact builds on Alnylam’s own pledge, encouraging biotech companies to be a force for good in partnering with European authorities, citizens and... Read More ›
June 24, 2020 Celebrating a Pride Month Unlike Any Other We asked members of our SAGA (Sexuality and Gender Alliance) employee resource network (ERN) how they've been celebrating Pride this year, given the Read More ›
June 1, 2020 We Stand Against All Forms of Racism and Discrimination On June 1, 2020, we issued the following public statement in response to events unfolding in the United States as a result of the killing of George Floyd and Read More ›

Get In Touch

Have any questions or comments about the content you see on this page?

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site